KPI data tables
Manulife operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | Hong Kong (incl. MCV) | Mainland China (Manulife-Sinochem JV) | Japan | Singapore | Emerging Asia (Vietnam + Other Emerging Markets) | International High Net Worth |
|---|---|---|---|---|---|---|
| 2025 | 1,965 | 1,180 | 460 | 1,118 | 372 | 155 |
| 2024 | 1,626 | 896 | 391 | 955 | 391 | 170 |
| 2023 | 903 | 723 | 243 | 823 | 404 | 170 |
Source: Manulife Financial Form 40-F annual MD&A, Asia segment APE by market in US$ millions: 2025 (filed 2026-02-11, https://www.sec.gov/Archives/edgar/data/1086888/000108688826000003/a2025annualmdareport.htm) and 2024 (filed 2025-02-19, https://www.sec.gov/Archives/edgar/data/1086888/000108688825000054/a2024annualmdareport.htm). 2023 is derived by dividing each 2024 figure by one plus the printed 2024 growth rate (constant exchange rate: Hong Kong 80%, mainland China 24%, Singapore 16%, Japan 61%, Vietnam -32%, Other Emerging Markets 12%, International High Net Worth in line). Years before 2023 are not printed per market and were removed.
| Period | Asia NBV |
|---|---|
| 2025 | 1,832 |
| 2024 | 1,516 |
| 2023 | 1,206 |
| 2022 | 1,181 |
| 2021 | 1,329 |
| 2020 | 1,037 |
Source: Manulife Financial annual MD&A, Asia segment Business Performance table, US$ columns (Form 40-F exhibits). 2020 US$1,037M: 2021 MD&A (https://www.sec.gov/Archives/edgar/data/1086888/000119312522032888/d274310dex992.htm). 2021 US$1,329M: 2021 MD&A. 2022 US$1,181M (IFRS 17 restated): 2023 MD&A (https://www.sec.gov/Archives/edgar/data/1086888/000119312524036601/d930980dex992.htm). 2023 US$1,206M: 2024 MD&A (https://www.sec.gov/Archives/edgar/data/1086888/000108688825000054/a2024annualmdareport.htm). 2024 US$1,516M (CAD 2,078M) and 2025 US$1,832M (CAD 2,560M): 2025 MD&A (https://www.sec.gov/Archives/edgar/data/1086888/000108688826000003/a2025annualmdareport.htm).
| Period | MLI LICAT Ratio (%) |
|---|---|
| Q3 2026 | 136 |
| Q2 2026 | 136 |
| Q1 2026 | 136 |
| Q4 2025 | 136 |
| Q3 2025 | 138 |
| Q1 2025 | 137 |
| Q4 2024 | 137 |
| Q3 2024 | 137 |
| Q2 2024 | 139 |
| Q1 2024 | 138 |
| Q4 2023 | 137 |
| Q3 2023 | 137 |
| Q2 2023 | 139 |
| Q1 2023 | 137 |
| Q4 2022 | 138 |
| Q3 2022 | 136 |
| Q2 2022 | 138 |
| Q1 2022 | 140 |
Source: Manulife quarterly earnings releases (SEC Form 6-K, CIK 0001086888) and Statistical Information Package (SIP). Q4 2025 (Dec 2025) and Q1 2026 (Mar 2026) MLI LICAT ratio both 136%. Q2 2026 136% (Q2 2026 press release, Form 6-K filed 2026-08-05, https://www.sec.gov/Archives/edgar/data/1086888/000108688826000080/q22026pressrelease.htm) and Q3 2026 136% (Q3 2026 press release, Form 6-K filed 2026-11-04, https://www.sec.gov/Archives/edgar/data/1086888/000108688826000104/q32026pressrelease.htm).
| Period | Asia | US (John Hancock) | Canada |
|---|---|---|---|
| 2025 | 2.12 | 0.86 | 1.17 |
| 2024 | 1.8 | 1.23 | 1.14 |
| 2023 | 1.52 | 1.3 | 1.1 |
| 2022 | 1.39 | 1.2 | 1.07 |
| 2021 | 1.74 | 1.54 | 0.94 |
| 2020 | 1.57 | 1.49 | 0.88 |
Source: Manulife Financial annual MD&A, core earnings by segment (Form 40-F exhibits), converted to US dollars at the full-year average rate Manulife prints in each MD&A (CAD per USD 1.3414 in 2020, 1.2536 in 2021, 1.3015 in 2022, 1.3494 in 2023, 1.3698 in 2024, 1.3974 in 2025). C$ millions Asia / Canada / U.S.: 2020 2,110 / 1,174 / 1,995 and 2021 2,176 / 1,179 / 1,936 (2021 MD&A, https://www.sec.gov/Archives/edgar/data/1086888/000119312522032888/d274310dex992.htm); 2022 1,812 / 1,387 / 1,566 (IFRS 17 restated) and 2023 2,048 / 1,487 / 1,759 (2023 MD&A, https://www.sec.gov/Archives/edgar/data/1086888/000119312524036601/d930980dex992.htm); 2024 2,466 / 1,568 / 1,690 (as updated for Global Minimum Tax) and 2025 2,969 / 1,634 / 1,206 (Q4 2025 earnings release, https://www.sec.gov/Archives/edgar/data/1086888/000108688826000007/a4q25pressrelease.htm, and 2025 MD&A, https://www.sec.gov/Archives/edgar/data/1086888/000108688826000003/a2025annualmdareport.htm).